Innate Immunotherapeutics' (IIL:$0.55) share price has been increasing steadily over the last three weeks on good volume. The stock is up 39% over this period, with the company's Phase IIb trial in secondary progressive multiple sclerosis (SPMS) now fully recruited. Results from this trial are due to be released in around 12 months time, in Q3 2017. On the back of those results, if positive, the company expects to secure a major transaction for its assets.
CEO Simon Wilkinson said that around 80% of patients in the current trial, which recruited 93 patients, are requesting to receive the active drug at the completion of the trial (under a Special Access Scheme in Australia and Compassionate Use arrangements in New Zealand). To date around 30 patients have finished 12 months of treatment, either with the placebo or active drug, MIS416.
For further information please download PDF attached:
Download this document
